S. R. Pattanaik
BACKGROUND Canagliflozin is a well-tolerated sodium-glucose transporter 2 inhibitor, with remarkable efficacy in providing glycaemic control in patients with type 2 diabetes mellitus (T2DM). However, limited evidence is available from national and international studies on the efficacy of the drug as an add-on to triple drug treatment for T2DM. The present study was aimed to evaluate the efficacy of canagliflozin (100 mg) as an add-on therapy in T2DM patients with inadequate disease control to triple drug treatment with glimepiride, metformin and teneligliptin. MATERIALS AND METHODS The prospective observational study was conducted in a clinical setting from Jan 2017 to March 2018. The study included T2DM patients showing inadequate disease control to triple drug treatment of glimepiride, metformin and teneligliptin. Clinical parameters such as body weight, HbA1c, systolic blood pressure, diastolic blood pressure, serum urea, creatinine, fasting and postprandial blood sugar levels were measured before and after the study. Comparison of pre- and post-treatment anthropometric and laboratory parameters were performed using paired t-test and Wilcoxon paired test. RESULTS The study included 51 patients with inadequately controlled T2DM, with an average age and BMI of 60 (47-68) and 23.78 (19.49-38.30) kg/m2 respectively. A statistically significant difference was noted in the pre-and post-treatment measures of HbA1c, body weight, blood pressure, fasting and post-prandial blood sugar levels. The creatinine levels did not show significant variation following the treatment. CONCLUSION Canagliflozin has demonstrated significant efficacy when used as an add-on drug to triple drug treatment of glimepiride, metformin and teneligliptin in T2DM patients with inadequate disease control.
